Key result
Minimizing time to treatment with 4-factor prothrombin complex concentrates using fixed dosing and increased infusion speed is critical for optimizing outcomes in VKA-related bleeding.
Why the study?
To examine real-world evidence and strategies to optimize INR reversal, hemostasis, and outcomes in patients receiving 4F-PCC for VKA-related bleeding.
What are the optimal dosage and administration practices for 4F-PCC in reversing VKA-related bleeding?
What are the optimal dosage and administration practices for 4F-PCC in reversing VKA-related bleeding?
Minimizing time to treatment and utilizing strategies like fixed dosing and increased infusion speed are crucial for optimizing 4F-PCC administration in VKA-related bleeding.
Alternative 4F-PCC dosing strategies may optimize VKA reversal; leaves open prospective trials to confirm outcome benefits.
Expert consensus and international guidelines recommend urgent co-administration of vitamin K and 4-factor prothrombin complex concentrates (4F-PCCs) to rapidly reverse VKA-related bleeding. This narrative review examined real-world evidence and strategies to optimize international normalized ratio (INR) reversal, hemostasis, and outcomes in patients receiving 4F-PCC in this setting. Key determinants for success include the appropriate use of alternative dosing and administration strategies, such as fixed dosing and increased infusion speed, adherence to institutional guidelines, and removing significant institutional barriers to reduce time to treatment. In the opinion of authors, minimizing the time to treatment with 4F-PCCs is of paramount importance when treating patients with VKA-related bleeding. Practices that safely and feasibly shorten the time to administration should be included in guidelines for institutions responsible for anticoagulant care, and adhered to in centers that perform invasive procedures on patients receiving VKA therapy. Further studies are required to optimize use of 4F-PCC, particularly in relation to the ideal dosing strategy and the role of INR.
No takes yet. Share an insight, caveat, or question.
Rhoney et al. (2020) conducted a review in VKA-related bleeding. 4-factor prothrombin complex concentrates (4F-PCCs) was evaluated. Minimizing time to treatment with 4-factor prothrombin complex concentrates using fixed dosing and increased infusion speed is critical for optimizing outcomes in VKA-related bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: